1199-33-3Relevant academic research and scientific papers
Benzothiazole-oxazole type alpha-glucosidase inhibitor and preparation method and application thereof
-
Paragraph 0022; 0023, (2018/10/19)
The invention discloses a benzothiazole-oxazole type alpha-glucosidase inhibitor and a preparation method and application thereof. The method comprises the following steps: adding a compound (II) andhydroxylamine hydrochloride in a methanol aqueous solution and a sodium carbonate aqueous solution to obtain a compound (III); adding the compound (III), zinc powder and ammonium formate in methanol and reacting to obtain a compound (IV); and adding the compound (IV), a compound (V), iodine and potassium carbonate in DMF and reacting to obtain a compound (I). The chemical formula of the compound (I) is as shown in specification, the chemical formula of the compound (II) is as shown in specification, the chemical formula of the compound (III) is as shown in specification, the chemical formula of the compound (IV) is as shown in specification, and the chemical formula of the compound (V) is as shown in specification. The benzothiazole-oxazole type compound has obvious inhibition effect on alpha-glucosidase, the preparation method is simple, reaction conditions are gentle, and thus, the benzothiazole-oxazole type alpha-glucosidase inhibitor is suitable for being industrially produced on alarge scale.
Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition
Goyard, David,Kónya, Bálint,Chajistamatiou, Aikaterini S.,Chrysina, Evangelia D.,Leroy, Jérémy,Balzarin, Sophie,Tournier, Michel,Tousch, Didier,Petit, Pierre,Duret, Cédric,Maurel, Patrick,Somsák, László,Docsa, Tibor,Gergely, Pál,Praly, Jean-Pierre,Azay-Milhau, Jacqueline,Vidal, Sébastien
supporting information, p. 444 - 454 (2015/12/24)
Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve
SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
-
Paragraph 00212-00213, (2015/05/19)
The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
